• Publications
  • Influence
Sphingopeptides: dihydrosphingosine‐based fusion inhibitors against wild‐type and enfuvirtide‐resistant HIV‐1
Understanding the structural organization of lipids in the cell and viral membranes is essential for elucidating mechanisms of viral fusion that lead to entry of enveloped viruses into their hostExpand
  • 27
  • 1
Medication detection by a combinatorial fluorescent molecular sensor.
Working together to uncover the truth: A molecule-sized diagnostic system combining several recognition elements and four fluorescence-emission channels enabled the identification of a wide range ofExpand
  • 59
  • PDF
Genetic risk for squamous cell carcinoma of the nictitating membrane parallels that of the limbus in Haflinger horses.
Squamous cell carcinoma (SCC) is the most common cancer affecting the equine eye, with a higher incidence documented in Haflinger horses. Recently, a missense variant in the gene damage specific DNAExpand
  • 8
AB1197 Multiparametric analysis of connective tissue disease specific autoantibodies using a spot immunoassay (SERASPOT®ANA)
Background Because autoantibody profiling compared to single autoantibody determination is more relevant for diagnostics, differential diagnostics and even prognostics of the different kinds ofExpand
PS2:44 Role of anti-dfs70 antibodies in the serological diagnostics of sle
Background Positive antinuclear antibosies (ANA) may lead to additional testing and potentially even inappropriate treatment in patients with rheumatic symptoms not caused by systemic lupusExpand
FRI0565 The Presence of Anti-DFS70 Antibodies Suggests Absence of Connective Tissue Diseases in Patients with Anti-Nuclear Antibodies (ANA)
Background Antinuclear antibodies (ANA) determined by the HEp-2 cell assay are the primary screening test for connective tissue diseases (CTDs), i.e. systemic lupus erythematosus (SLE), mixedExpand
THU0674 ANTI-DFS70 antibody – a biomarker that aid in the exclusion of ana associated rheumatic diseases
Background Positive ANA may lead to additional testing and potentially even inappropriate treatment in patients with rheumatic symptoms not caused by ANA associated rheumatic diseases (AARD).Expand